PUFAs and Left Ventricular Function in Heart Failure

PHASE3CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Dilated CardiomyopathyHeart Failure
Interventions
DRUG

n-3 PUFAs

1.0 g gelatin capsules containing 850 to 882 mg of EPA and DHA ethyl esters in the average ratio EPA/DHA of 0.9:1.5 The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study.

DRUG

Placebo

1.0 g gelatin capsules containing olive oil. The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study

Trial Locations (1)

25100

Arrhytmias and Heart failure Unit-Spedali Civili Hospital, Brescia

All Listed Sponsors
lead

Università degli Studi di Brescia

OTHER

NCT01223703 - PUFAs and Left Ventricular Function in Heart Failure | Biotech Hunter | Biotech Hunter